Human cytomegalovirus (HCMV) is a herpesvirus that infects~ 60% of adults in developed
countries and more than 90% in developing countries. Usually, it is controlled by a vigorous …

This review focuses on recent advances in the field of cytomegalovirus (CMV). The 2 main
strategies for CMV prevention are prophylaxis and preemptive therapy. Prophylaxis …

Decreased cytomegalovirus (CMV)-specific immunity after hematopoietic cell transplantation
(HCT) is associated with late CMV reactivation and increased mortality. Whether letermovir …

Importance Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral
prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive …

Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS,
transplant recipients, and fetuses, are at the highest risk for complications from …

While CD8+ T cells specific for human cytomegalovirus (HCMV) have been extensively
studied in both healthy HCMV seropositive carriers and patients undergoing …

Since murine cytomegalovirus (MCMV) was first described in 1954, it has been used to
model human cytomegalovirus (HCMV) diseases. MCMV is a natural pathogen of mice that …

Solid organ transplant recipients (SOTRs) are at high risk of human herpesvirus (HHV)-
related morbidity and mortality due to the use of immunosuppressive therapy. We aim to …

Background The relative costs of preemptive therapy (PET) or prophylaxis for the prevention
of cytomegalovirus (CMV) disease in high-risk donor CMV-seropositive/recipient …

Background The optimal regimen for preventing cytomegalovirus (CMV) infection in kidney
transplant recipients, primarily in reducing indirect CMV effects, has not been defined …